Seroconversion rates following COVID-19 vaccination among patients with cancer

  1. Astha Thakkar
  2. Jesus D. Gonzalez-Lugo
  3. Niyati Goradia
  4. Radhika Gali
  5. Lauren C. Shapiro
  6. Kith Pradhan
  7. Shafia Rahman
  8. So Yeon Kim
  9. Brian Ko
  10. R. Alejandro Sica
  11. Noah Kornblum
  12. Lizamarie Bachier-Rodriguez
  13. Margaret McCort
  14. Sanjay Goel
  15. Roman Perez-Soler
  16. Stuart Packer
  17. Joseph Sparano
  18. Benjamin Gartrell
  19. Della Makower
  20. Yitz D. Goldstein
  21. Lucia Wolgast
  22. Amit Verma
  23. Balazs Halmos

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.ccell.2021.06.002
  2. ScreenIT

    SciScore for 10.1101/2021.05.07.21256824: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: Patient data collection: The study was approved by the Montefiore-Einstein Institutional Review Board.
    Consent: Participants were enrolled in the study after signing informed consent.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    SARS-CoV-2 Spike IgG assay: The AdviseDx SARS-CoV-2 IgG II assay was used for the assessment of anti-spike IgG antibody testing.
    anti-spike IgG
    suggested: None
    The assay is designed to detect IgG antibodies directed against the receptor binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2.
    detect IgG
    suggested: None
    The mixture is then washed of unbound IgG and anti-human IgG, acridinium-labeled, secondary antibody is added and incubated.
    anti-human IgG
    suggested: None
    There is a direct relationship between the amount of IgG anti-spike antibody and the RLU detected by the system optics.
    anti-spike
    suggested: None
    Software and Algorithms
    SentencesResources
    AdviseDx is an automated, two-step chemiluminescent immunoassay performed on the Abbott i2000SR instrument.
    Abbott
    suggested: (Abbott, RRID:SCR_010477)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Another potential limitation is under-estimation of titer values for anti-spike antibodies as evidence suggests titers may rise over time36, however, a cut-off of 7 days was used to match the control cohort and eliminate bias in the analysis. Our study along with other emerging data strongly highlights the continued need to invest strong efforts to vaccinate patients with a cancer diagnosis urgently and broadly as vaccinations are likely to be highly effective. On the other hand, our study highlights vulnerable cohorts of patients, in particular patients with hematological malignancies following receipt of highly immune suppressive therapies- stem cell transplant, anti-CD20 therapies, CAR-T cell treatments37These cohorts of patients will need unique considerations and urgent plans to novel vaccination strategies as well as possibly passive protection strategies in the face of the ongoing pandemic- such as protective antibody therapies. In summary, we present a large cohort of patients with malignancy who underwent full COVID-19 vaccination according to FDA established guidance. In this cohort of ethnically diverse patients with broad representation of a wide range of malignancies and therapies, encouragingly very high seropositivity rates were observed in contrast from previously published small cohort studies focused on unique subsets of susceptible patients or non-standard vaccination schedules. Statistically significantly lower seropositivity rates were observed in patient...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.05.07.21256824v1 on medRxiv